抗凝剂和痴呆症:一个系统性审查
Amy E Kalloo1, Ethan Slouha2, Connor P Gallagher2
1Clinical Sciences, St. George's University School of Medicine, True Blue, GRD.
Cureus
|July 3, 2023
概括
抗凝药可以保护心房动 (AF) 患者免受痴呆症的影响. 直接口服抗凝剂 (DOACs) 显示出保护作用,而维生素K对抗剂 (VKAs) 则具有混合的结果,抗血小板治疗可能会增加痴呆风险.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心房动 (AF) 经常与痴呆症的发展有关.
- 抗血栓药物是AF患者中风预防的标准.
- 新出现的证据表明,抗凝血剂可能会在AF中提供对痴呆症的保护.
研究的目的:
- 为了系统地审查心房患者痴呆的发病率,处方抗凝剂.
- 分析各种抗凝血剂类对痴呆风险的影响.
主要方法:
- 关于实验研究和元分析的综合文献综述.
- 在PubMed,ProQuest和ScienceDirect上使用与痴呆和抗凝药相关的关键词进行的搜索.
- 纳入和排除标准适用于53,306篇初始文章,导致29篇精选研究.
主要成果:
- 口服抗凝剂 (OACs) 总体上显示,痴呆的风险降低.
- 直接口服抗凝剂 (DOAC) 特别与痴呆症保护有关.
- 维生素K对抗剂 (VKA) 在痴呆风险方面产生了相互矛盾的结果,华法林显示了一些益处,但低于DOACs.
- 抗血小板治疗与AF患者痴呆风险增加有关.
结论:
- 在AF患者中,DOAC证明了对AF患者痴呆的潜在保护作用.
- 维卡在痴呆症预防中的作用是不确定的,报告的结果各不相同.
- 在这种人群中,抗血小板治疗可能与痴呆症的风险增加有关.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Dementia
141
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
141
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527


